CELGCelgene Corporation
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025...
PR Newswire·8d ago
Bristol Myers Squibb to Present Data at ESMO 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2025 to be held from...
Business Wire·12d ago
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration PR...
PR Newswire·12d ago
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics
Bristol Myers Squibb (NYSE: BMY, BMS) and Orbital Therapeutics (Orbital) today announced a definitive agreement under which BMS will acquire Orbital, a privately held biotechnology company pioneering...
Business Wire·15d ago
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection
Bristol Myers Squibb (NYSE: BMY) today announced the launch of its COBENFY Connections initiative in partnership with culinary expert, TV host and author Gail Simmons.* Launching on World Mental...
Business Wire·15d ago
Bristol Myers Squibbs Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for...
Business Wire·3mo ago
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2025. The company will participate in a fireside chat at the TD Cowen...
Business Wire·8mo ago
U.S. Food and Drug Administration Accepts Bristol Myers Squibbs Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
U.S. Food and Drug Administration Accepts Bristol Myers Squibbs Supplemental Biologics License Application for Opdivo Plus Yervoy for Patients with Unresectable or Metastatic Microsatellite...
Business Wire·8mo ago
Bristol Myers Squibb Announces Opdivo Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo (nivolumab) in combination with...
Business Wire·8mo ago
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb (NYSE:BMY) today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with...
Business Wire·8mo ago